Atara Biotherapeutics, Inc. announced a Type A meeting with the FDA to discuss the Complete Response Letter for the EBVALLO Biologics License Application. This meeting aims to address points from the CRL and facilitate a resubmission with additional efficacy data.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.